Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0136 | 0.5677 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0136 | 0.5677 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0136 | 0.5677 | 0.5677 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0121 | 0.4632 | 0.5 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0121 | 0.4632 | 0.8159 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0136 | 0.5677 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0121 | 0.4632 | 0.8159 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0136 | 0.5677 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0136 | 0.5677 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.5677 | 0.5677 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0068 | 0.1115 | 0.0151 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0136 | 0.5677 | 1 |
Leishmania major | p450 reductase, putative | 0.0136 | 0.5677 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0136 | 0.5677 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0136 | 0.5677 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0084 | 0.216 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0084 | 0.216 | 0.216 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0136 | 0.5677 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.0121 | 0.4632 | 0.8159 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0136 | 0.5677 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0136 | 0.5677 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0136 | 0.5677 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0084 | 0.216 | 0.2407 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0052 | 0 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0067 | 0.1045 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0136 | 0.5677 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0136 | 0.5677 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0052 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0084 | 0.216 | 0.216 |
Giardia lamblia | Hypothetical protein | 0.0121 | 0.4632 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0136 | 0.5677 | 0.5677 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0067 | 0.1045 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0136 | 0.5677 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0052 | 0 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0136 | 0.5677 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0052 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0136 | 0.5677 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0136 | 0.5677 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0136 | 0.5677 | 0.5677 |
Treponema pallidum | flavodoxin | 0.0052 | 0 | 0.5 |
Loa Loa (eye worm) | receptor family ligand binding region containing protein | 0.02 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0052 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED30 (functional) | > 20 uM | Dose required for 30% clonal survival of ER positive MCF-7 breast cancer cells after 2 hr | ChEMBL. | 15203171 |
ED30 (functional) | > 20 uM | Dose required for 30% clonal survival of ER negative MDA-MB231 breast cancer cells after 2 hr | ChEMBL. | 15203171 |
Oligo shifted (functional) | = 93 % | Percent of covalently modified 16-mer (DNA adduct) in a slowly migrating complex with ER ligand binding domain (ER-LBD) in EMSA electrophoretic mobility shift assay | ChEMBL. | 15203171 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.